United Kingdom· GB-APID-43487111000001100
Simulect 20mg powder for solution for injection vials
A basiliximab product containing basiliximab, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Basiliximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC02 (basiliximab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Basiliximab · ATC L04AC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Basiliximab
- Manufacturer
- Novartis Pharmaceuticals UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L04AC02
- ATC class
- Basiliximab
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin07613421172718
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for basiliximab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Basiliximab · interactions on record
60 records
- 27 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Basiliximab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSimulectOrifarm Oy
- BelgiumSimulect 10 mgNovartis Europharm
- CzechiaSIMULECTNovartis Europharm Limited, Dublin
- IcelandSimulectNovartis Europharm Limited*
- SwedenSimulect 10 mg Pulver och vätska till injektions-/infusionsvätska, lösningNovartis Europharm Limited
- Japanバシリキシマブ（遺伝子組換え）ノバルティス ファーマ
- NetherlandsSimulect 10 mg, poeder en oplosmiddel voor oplossing voor intraveneuze infusieNovartis Europharm Limited
- NorwaySimulectNovartis Europharm Limited (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Simulect
- Liechtenstein · Simulect
- Norway · Simulect
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f454595c-692f-40b5-aeb2-d04fdc955f62 GET /v1/drugs/f454595c-692f-40b5-aeb2-d04fdc955f62?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "43487111000001100",
"desc": "Simulect 20mg powder for solution for injection vials (Novartis Pharmaceuticals UK Ltd)",
"form": "Powder for solution for injection",
"vpid": "43532911000001101",
"source": "dmd",
"vtm_id": "774741008",
"strength": "20 mg",
"substance": "Basiliximab",
"ingredient": "Basiliximab",
"supplier_code": "2920101000001102"
}See everything about basiliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.